| Trial ID: | L1929 |
| Source ID: | NCT00638131
|
| Associated Drug: |
Bosentan
|
| Title: |
Bosentan Use in Patients With Diabetic Nephropathy
|
| Acronym: |
|
| Status: |
TERMINATED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: bosentan
|
| Outcome Measures: |
Primary: change from baseline to week 16 in renal inflammation. The following urinary inflammatory/oxidative stress parameters will be measured: - TNF, 16 weeks | Secondary: change from baseline to week 16 in renal functioning. The following renal function parameter will be measured: - 24h UAE;, 16 weeks
|
| Sponsor/Collaborators: |
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) | Collaborators: Actelion
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
1
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2009-01
|
| Completion Date: |
2010-06
|
| Results First Posted: |
|
| Last Update Posted: |
2020-07-24
|
| Locations: |
CHUM, Montreal, Quebec, H2L 4M1, Canada
|
| URL: |
https://clinicaltrials.gov/show/NCT00638131
|
